Edwards Lifesciences Seen Building on Catalyst Pipeline, RBC Says

MT Newswires Live07-24

Edwards Lifesciences (EW) is competitively differentiated and positioned to sustain double-digit growth as product catalysts build through 2027, RBC Capital Markets said in a Thursday note.

Meanwhile, Q2 results reinforced that view as transcatheter aortic valve replacement, or TAVR, sales exceeded expectations, supported by market growth and modest share gains, the note said.

RBC also pointed to continued clinical momentum and adoption of the Sapien 3 Ultra platform.

Regulatory and pipeline developments continue to support its growth outlook, including a final US national coverage determination for TAVR expected in September, trial result and anticipated US approval of Pascal, the note said.

RBC raised its 2026 revenue estimate to $6.76 billion and said it continues to expect adjusted EPS of $3.02.

RBC reiterated its outperform rating on Edwards Lifesciences and $110 price target.

Price: 85.47, Change: +1.65, Percent Change: +1.97

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment